Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...

Key takeaways: Ulcerative pyoderma gangrenosum is a rare disease with no current treatment. Vilobelimab has been granted orphan drug and fast track designations by the FDA. InflaRx has initiated a ...

The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG), a rare skin disorder characterized by chronic ...

But having ulcerative colitis doesn’t mean you’re going to get pyoderma gangrenosum. Fewer than 3% of people with an inflammatory bowel disease develop the skin condition.

The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).

Unlike many other ulcerative colitis–related skin conditions, pyoderma gangrenosum can appear even when someone's IBD is well-controlled, Dr. DeWane notes.

Ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), is often associated with extraintestinal complications — those that occur in other parts of the body, such as the skin, eyes ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...